LX
Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
$2.24 -0.44% (-$0.01)
1M -6.67%
Market Cap $995.0M
P/E Ratio -
Div. Yield -
ROE 40.40%
Bulios Fair Price
$3.25
45.1% upside
Trenutna cena
$2.24
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica LXRX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
15 /100
Expensive P/S 23.99x
P/B 5.70x
P/E N/A
Growth
80 /100
Growing Rev. growth 610.25%
Book val. growth 2.81%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 98.85%
FCF margin 192.24%
Net margin 147.38%
Quality
2 /100
Poor ROIC 23.00%
Asset turnover 0.17x
ROE 40.40%
Debt
68 /100
Low Debt/Equity 0.34x
Int. coverage -6.29x
Current ratio 13.37x
Stability
32 /100
Unstable Beta 1.03x
Profitable years 0
Rev. volatility 1,245.19%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Exton
Employees
81
Headquarters
The Woodlands
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report